Anti-metastatic effect of cantharidin in A549 human lung cancer cells

Archives of Pharmacal Research

Volumn 36, Issue 4, 2013, Pages 479-484

  Kim, Young Min ^a   Ku, Min Jeong ^a   Son, Young Jin ^b   Yun, Jung Mi ^c   Kim, Seong Hwan ^d   Lee, Sang Yeol ^a  

^a Gachon University   (South Korea)

^b Sunchon National University   (South Korea)

^c Kwangju Women University   (South Korea)

^d Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Cantharidin; Human lung cancer; Matrix metalloproteinases; Metastasis

Indexed keywords

CANTHARIDIN; GELATINASE A; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATTENUATION; CELL MIGRATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG INHIBITION; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; LUNG CANCER; SIGNAL TRANSDUCTION; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; CANTHARIDIN; CELL LINE, TUMOR; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE INHIBITORS; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84877875984     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0044-3     Document Type: Article

References (20)

1. Attiga, F.A., P.M. Fernandez, A.T. Weeraratna, M.J. Manyak, and S.R. Patierno. 2000. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Research 60: 4629-4637.
2. Bae, I.H., M.J. Park, S.H. Yoon, S.W. Kang, S.S. Lee, K.M. Choi, and H.D. Um. 2006. Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1. Cancer Research 66: 4991-4995.
3. Basset, P., A. Okada, M.P. Chenard, R. Kannan, I. Stoll, P. Anglard, J.P. Bellocq, and M.C. Rio. 1997. Matrix metalloproteinases as stromal effectors of human carcinoma progression: Therapeutic implications. Matrix Biology 15: 535-541.
4. Carnero, A., C. Blanco-Aparicio, O. Renner, W. Link, and J.F. Leal. 2008. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Current Cancer Drug Targets 8: 187-198.
5. Chen, Y.J., W.M. Chang, Y.W. Liu, C.Y. Lee, Y.H. Jang, C.D. Kuo, and H.F. Liao. 2009. A small-molecule metastasis inhibitor, norcantharidin, downregulates matrix metalloproteinase-9 expression by inhibiting Sp1 transcriptional activity in colorectal cancer cells. Chemico-Biological Interactions 181: 440-446.
6. Chu, S.C., D.N. Hu, S.F. Yang, P.Y. Yang, Y.S. Hsieh, S.M. Huang, G. Yu, and S.A. McCormick. 2004. Uveal melanocytes produce matrix metalloproteinases-2 and -9 in vitro. Pigment Cell Research 17: 636-642.
7. Deryugina, E.I., and J.P. Quigley. 2006. Matrix metalloproteinases and tumor metastasis. Cancer and Metastasis Reviews 25: 9-34.
8. Huang, C., K. Jacobson, and M.D. Schaller. 2004. MAP kinases and cell migration. Journal of Cell Science 117: 4619-4628.
9. Johnsen, M., L.R. Lund, J. Rømer, K. Almholt, and K. Danø. 1998. Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation. Current Opinion in Cell Biology 10: 667-671.
10. Kok, S.H., C.H. Chui, W.S. Lam, J. Chen, F.Y. Lau, G.Y. Cheng, R.S. Wong, P.P. Lai, T.W. Leung, J.C. Tang, and A.S. Chan. 2006. Apoptotic activity of a novel synthetic cantharidin analogue on hepatoma cell lines. International Journal of Molecular Medicine 17: 945-949.
11. Li, W., L. Xie, Z. Chen, Y. Zhu, Y. Sun, Y. Miao, Z. Xu, and X. Han. 2010. Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis. Cancer Science 101: 1226-1233.
12. Massicot, F., H. Dutertre-Catella, C. Pham-Huy, X.H. Liu, H.T. Duc, and J.M. Warnet. 2005. In vitro assessment of renal toxicity and inflammatory events of two protein phosphatase inhibitors cantharidin and norcantharidin. Basic Clinical Pharmacology and Toxicology 96: 26-32.
13. Nelson, A.R., B. Fingleton, M.L. Rothenberg, and L.M. Matrisian. 2000. Matrix metalloproteinases: Biologic activity and clinical implications. Journal of Clinical Oncology 18: 1135-1149.
14. Nyberg, P., T. Salo, and R. Kalluri. 2008. Tumor microenvironment and angiogenesis. Frontiers in Bioscience 13: 6537-6553.
15. Sahai, E. 2007. Illuminating the metastatic process. Nature Reviews Cancer 7: 737-749.
16. Sato, H., and M. Seiki. 1993. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8: 395-405.
17. Van den Steen, P.E., B. Dubois, I. Nelissen, P.M. Rudd, R.A. Dwek, and G. Opdenakker. 2002. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Critical Reviews in Biochemistry and Molecular Biology 37: 375-536.
18. Vivanco, I., and C.L. Sawyers. 2002. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Reviews Cancer 2: 489-501.
19. Westermarck, J., and V.M. Kähäri. 1999. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB Journal 13: 781-792.
20. ® (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pacific Journal of Cancer Prevention 13: 4773-4776.